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Frontometaphyseal dysplasia (FMD) is a progressive sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in
some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains un-
known. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to
individuals with FLNA mutations, except for an increased tendency to form keloid scars. Using whole-exome sequencing and targeted
Sanger sequencing in 19 FMD-affected individuals with no identifiable FLNAmutation, we identifiedmutations in two genes—MAP3K7,
encoding transforming growth factor b (TGF-b)-activated kinase (TAK1), and TAB2, encoding TAK1-associated binding protein 2 (TAB2).
Fourmutations were found inMAP3K7, including one highly recurrent (n¼ 15) de novomutation (c.1454C>T [ p.Pro485Leu]) proximal
to the coiled-coil domain of TAK1 and three missense mutations affecting the kinase domain (c.208G>C [p.Glu70Gln], c.299T>A
[p.Val100Glu], and c.502G>C [p.Gly168Arg]). Notably, the subjects with the latter three mutations had a milder FMD phenotype.
An additional de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1,
or impair its ability to homodimerize or bind TAB2, but it does increase TAK1 autophosphorylation and alter the activity of more
than one signaling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex pro-
duces a close phenocopy of FMD caused by FLNAmutations. Furthermore, they suggest that the pathogenesis of some of the filamino-
pathies caused by FLNAmutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex.Introduction
Frontometaphyseal dysplasia (FMD [MIM: 305620]) is a
progressive sclerosing skeletal dysplasia characterized by
supraorbital hyperostosis, undermodeling of the long
bones, small and large joint contractures, and other extra-
skeletal developmental abnormalities, most notably of the
cardiorespiratory system and genitourinary tract.1 An
X-linked form of FMD has been clearly defined, and
in this condition, males manifest most prominently,
although females can express a milder phenotype that in-
cludes hyperostosis and limb anomalies.2,3 The severity of
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 2016 American Society of Human Genetics.near-normal adaptive functioning to perinatal lethality,
principally due to the consequences of the extraskeletal
malformations.3 The hyperostosis observed in FMD is
not associated with bone fragility, and the excess cortical
bone has the histological appearance of mature lamellar
bone.
Gain-of-function mutations in FLNA (MIM: 300017),
located on the X chromosome and encoding the actin-
binding protein filamin A, account for FMD in ~50% of in-
dividuals.3 This form of the condition is allelic to a spec-
trum of related phenotypes known as the otopalatodigital
spectrum disorders (OPDSDs).2,4 The mutations leading
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deletions and insertions that are clustered throughout the
coding regions of FLNA, some of which are highly recur-
rent.2,5,6 Many of these mutations, including some leading
to FMD,3 result in the substitution of residues in the N-ter-
minal actin-binding domain of the protein. The effect of
FMD-associated mutations on the function of this domain
has not been explicitly addressed, but a recurrent missense
mutation leading to the allelic disorder otopalatodigital
syndrome type 2 (OPD2 [MIM: 304120]) confers enhanced
avidity for actin.7 How this activity results in malforma-
tions in addition to hyperostosis is unknown, but the
mechanism could relate to one or more of the many
and varied biochemical functions of filamin A that include
engagement with integrin-mediated cell-cell adhesion,8–10
cytoskeletal remodeling,11,12 cell spreading and migra-
tion,13 mechanotransduction,14,15 and influencing many
cell signaling pathways through physical interactions
with a multiplicity of second messenger proteins.16
Around 50% of individuals with a diagnosis of FMDhave
no demonstrable mutation in FLNA.3,17 These individuals
are almost indistinguishable phenotypically from those
with FLNA-mutation-positive FMD,3,17 one notable differ-
ence being the preponderance for individuals without an
identifiable FLNAmutation to develop keloid scarring. Un-
like X-linked FMD, the severity of the phenotype does not
vary between the sexes, although females aremore likely to
develop keloid, similar to the presentation of this sporadi-
cally arising cutaneous condition.17 The majority of indi-
viduals with the FMD phenotype not explained by a
FLNA mutation are isolated cases in their families; only
rare instances of vertical transmission of the phenotype
have been reported.3,17,18
Here, we analyze 19 individuals with FMD who do
nothave an identifiable FLNAmutation andfindmutations
in two genes encoding components of the transforming
growth factor b (TGF-b)-activated kinase (TAK1) signaling
complex in all subjects. Strikingly, 15 individuals have a
recurrent mutation in MAP3K7 (MIM: 602614), which en-
codes for TAK1. We show that these mutations result in
enhanced TAK1 autophosphorylation and alteration of
MAPK and NF-kB signal transduction emanating from
this protein complex. Three additional individuals have
missense mutations in the MAP3K7 region that encodes
the kinase domain. These mutations produce a notably
milder phenotype, which suggests a domain-specific
phenotype-genotype correlation in this form of FMD.
These results place TAK1 as a key regulator of several cell
signalingpathways that coordinately regulate osteogenesis.Material and Methods
Subject Ascertainment and Ethical Approval
Individuals with FMD were recruited by physician-initiated
referral and consented to participate under approved protocols
MEC/08/08/094 and 13/STH/56 (Health and Disability Ethics
Committee, New Zealand). Subjects were diagnosed with FMD
on the basis of clinical and radiological assessment, according toThe Amerpublished criteria.3 Sanger sequencing of FLNA did not detect
any mutations. Where possible, DNA was also collected from par-
ents and siblings, and familial relationships were confirmed as
declared by the examination of the segregation of six unlinkedmi-
crosatellite markers.Whole-Exome Sequencing
Identification of candidate genetic variants was initially per-
formed with exome sequence data from parent-proband trios for
four simplex individuals (01, 02, 05, and 17). Additional Sanger
and exome sequencing was carried out on samples from the re-
maining 15 subjects. Genomic DNAwas extracted from peripheral
blood according to standard protocols. Parental DNAwas available
from ten families.
For three trios (subjects 01, 02, and 05 and their parents), exome
enrichment was performed with the Agilent SureSelect Human All
ExonV4þUTRs capture kit, andpaired-end sequencing (generating
100 base-pair reads) was performed on the Illumina HiSeq2000
sequencingplatform. Sequencing datawere aligned to the Ensembl
Genome browser human genome assembly (GRCh37) with the
Burrows-Wheeler Aligner (MEM algorithm) v.0.7.12. Realignment
around indels, marking of duplicate reads, and recalibration of
base quality scores, was undertaken with tools from Picard
v.1.140 (Broad Institute) and the Genome Analysis Toolkit
(GATK) v.3.4-46 (Broad Institute). Individual variant calling was
undertakenwith theGATKHaplotypeCaller and followedbymulti-
sample genotyping and variant quality score recalibration. Gene
context annotation was added with SnpEff v.4.1L, and allele fre-
quencies were obtained from 1000 Genomes Project phase 1,
NHLBI GO Exome Sequencing Project ESP6500, and the Exome
Aggregation Consortium (ExAC) via the GATK VariantAnnotator.
Sequential filtering of the multisample VCF file was undertaken
with GATK SelectVariants and SnpSift v.4.1L (SnpEff). Subse-
quently, this protocolwas carried out on individual 14. For samples
from subjects 17, 18, and 19 and their respective parents, exome
enrichmentwasperformedwithan IlluminaTruSeqExomeEnrich-
ment kit. Massively parallel sequencing was performed with the
Illumina HiSeq2000 platform, generating 100 base-pair paired-
end reads.Demultiplexing, base calling, alignment, variant calling,
and annotation of these trios was performed as described
previously.19 For all individuals analyzed by exome sequencing,
platformartifactswere removedandgoodquality, rare variants (mi-
nor allele frequency < 0.001) in coding regions (including splice
sites and 50 and 30UTRs) were retained (Table S4). De novo variants
(present in the affected child but not in either parent) were then
identified for each individual. Candidate mutations, and their de
novo status, were confirmed by Sanger sequencing in subjects
and their parents. Samples from subject 12 and their parents were
exome sequenced with a slightly different protocol and analytical
pipeline that has been described previously.20 Directed Sanger
sequencing of the two candidate genes was performed in 12 addi-
tional individuals (for primer sequences, see Table S1).cDNA Preparation and RT-PCR
Primary dermal fibroblasts from individuals with MAP3K7-muta-
tion-positive FMD were cultured in DMEM (Gibco, Thermo
Fisher), plus 10% fetal bovine serum (FBS; Moregate) and 1%
streptomycin and penicillin (Gibco). RNA was extracted with
Trizol reagent (Thermo Fisher) and the Nucleospin RNA kit
(Machery-Nagel), according to kit protocols. cDNA was reverse-
transcribed from total RNA with the SuperScriptIII kit (Thermoican Journal of Human Genetics 99, 392–406, August 4, 2016 393
Fisher), according to the kit protocol. PCR amplification and
Sanger sequencing was carried out with primers listed in Table S1.Generation of Expression Constructs
The full coding sequence of MAP3K7 (variant A21 [GenBank:
NM_003188.3]) was amplified from HEK293 cDNA with primer
pair 1 (for all primer sequences, see Table S2) and cloned into
pcDNA3.1 with the TOPO cloning kit (Thermo Fisher). This
transcript was selected for these studies because (1) it represents
the form that contains exon encoding sequences subject to
mutation in the disorder under study, and (2) it represents the iso-
form studied by the vast majority of investigations into the
properties of this gene. Primer pairs two, three, and four
were used to sub-clone MAP3K7 into EcoRI- and XbaI-restriction-
digested pCMV-Myc, pCMV-HA, and p3xFLAG-CMV with the
Gibson assembly kit (NE Biolabs). TAB2 (GenBank: NM_015093.
5) was amplified from HEK293 cDNA with primer pair four and
cloned into pcDNA3.1 with TOPO cloning. Primer pair 5 was uti-
lized for the sub-cloning of TAB2 into EcoRI- and XbaI-digested
pCMV-HA with the Gibson assembly. TAB1 (pT7-FLAG) was a
kind gift from K. Matsumoto (Nagoya University). Mutagenesis
in MAP3K7 was carried out with overlapping amplicons contain-
ing the mutagenized base, followed by Gibson Assembly.Co-immunoprecipitation
For competitive co-immunoprecipitation of TAK1 and TAB2,
HEK293FT cells were cultured in DMEM (Gibco) plus 10% FBS
(Moregate) and co-transfected with one of the following, using
Lipofectamine2000 (Thermo Fisher) in a 24-well plate: (1)
pCMV-HA TAB2 (800 ng), pCMV-MYC TAK1 (10 ng), and
p3XFLAG TAK1 (10 ng), (2) pCMV-HA TAB2 (800 ng), pCMV-
MYC TAK1 (10 ng), and p3XFLAG TAK1 p.Pro485Leu (10 ng),
(3) pCMV-MYC TAK1 (10 ng) and p3XFLAG TAK1 (10 ng), or (4)
pCMV-MYC TAK1 (10 ng) and p3XFLAG TAK1 p.Pro485Leu
(10 ng). For analysis of TAK1 dimerization by competitive co-
immunoprecipitation, HEK293FT cells were co-transfected with
one of the following, using the same protocol: (1) pCMV-HA
TAK1 (250 ng), pCMV-MYC TAK1 (250 ng), and p3XFLAG TAK1
(250 ng) or (2) pCMV-HA TAK1 (250 ng), pCMV-MYC TAK1
(250 ng), and p3XFLAG TAK1 p.Pro485Leu (250 ng). After 20 hr,
cells were lysed in 13 PBS and 1% Triton X100 with protease inhib-
itor (cOmplete mini, Roche). Lysates were clarified by centrifuga-
tion and 30 mL was retained for input samples. 2 mL of mouse
anti-HA (Sigma Aldrich, H3663) was added to 150 mL supernatant,
and samples were mixed at 4C for 4 hr. 50 ml of washed Protein G
Dynabeads (Thermo Fisher) were added to each sample and incu-
bated for a further 30min at 4C, followed by three 1mLwashes in
PBS. Protein was eluted in SDS sample buffer, and samples were
resolved by 7% SDS-PAGE, followed by transfer to a nitrocellulose
membrane. Membranes were blocked in 5% milk (PBS) then incu-
bated with either mouse anti-HA (1:5,000, Sigma Aldrich, H3663),
mouse anti-MYC (1:5,000, Clontech, 631206), or mouse anti-
FLAG (1:7,000, Sigma Aldrich, F1804), followed by secondary
goat anti-mouse IRDye 800CW (1:25,000, LI-COR, 926-32210).
Membranes were scanned on a LI-COR Odyssey Clx, and bands
were quantified with LI-COR Image Studio Lite software.Luciferase Assays
HEK293 cells were cultured as previously described and trans-
fected in a 24-well plate with 100 ng of plasmid DNA per well
with Lipofectamine2000. Transfections were harvested 20 hr394 The American Journal of Human Genetics 99, 392–406, August 4later in passive lysis buffer and assayed for Renilla and firefly
luciferase activities with a Synergy2 multi-mode reader (BioTek)
and injector module, which delivered the respective luciferase
assay buffers (Promega). MAPK activity was assayed with the
pFR-luc and pFA-ELK1 Pathdetect vectors (Agilent), which detect
MAPK phosphorylation of the GAL4-ELK1 fusion protein and
subsequent transcription from the pFR-luc reporter. NF-kB activ-
ity was measured from the reporter pNF-kBREluc (pGL4.32
[luc2P/NF-kB-RE/Hygro]; Promega). DNA constructs were trans-
fected with the following amounts (ng/well): pFRluc (10), pFA-
ELK1 (10), pNF-kBREluc (5), pSVminRL (10–45), pTAK1 and
mutants (10), pHA-TAB2 and mutant (40), and pCR3.1 (as empty
vector) (10–50).
Western Blotting
For TAK1 stability, HEK293FT cells were transfected with 20 ng
p3XFLAG TAK1 (wild-type [WT], p.Pro485Leu, or p.Gly168Arg)
and treated with 85 mg/mL cycloheximide in DMSO or equiva-
lent DMSO control after 24 hr. For quantification of phospho-
TAK1, HEK293FT cells were transfected with 40 ng pCMV-HA
TAB2 (WT or p.Glu569Lys), 20 ng pT7-FLAG TAB1, and 20 ng
p3XFLAG TAK1 (WT and mutants) with Lipofectamine2000 in
a 24-well plate. Transfections for phosphorylated p38 (p-p38)
western blots were carried out as for luciferase assays. After
24 hr, cells were lysed in 13 PBS and 1% TritonX100 with
protease inhibitor; supernatant was cleared by centrifugation.
Samples were denatured in 2.3% SDS and 1% DTT buffer.
Proteins were resolved by electrophoresis on 8% polyacrylamide
gels, followed by transfer to nitrocellulose membrane. Mem-
branes were blocked in 5% milk (PBS) or Odyssey PBS
buffer (LI-COR) and probed for 1 hr to overnight with anti-
FLAG (F1804, Sigma Aldrich; 1:7000), anti-Myc (631206, Ta-
kara/Clontech; 1:5000), anti-phospho-TAK1 (Thr187, 1:1,500,
Cell Signaling, CST4536), anti-p38 (1:2,000, Cell Signaling,
CST9212), or anti-p-p38 (Thr180/Tyr182, CST9216, Cell Sig-
naling Technologies; 1:4000). Detection was done with second-
ary goat anti-mouse IRDye 800CW (1:25,000, LI-COR, 926-
32210) and goat anti-rabbit IRDye 700CW (1:25,000, LI-COR,
926-68071) antibodies as described above.
Statistical Analysis
Quantitative data from western blots and luciferase assays was
imported into Excel and scaled and normalized to appropriate
controls. Two-way, unpaired t tests were carried out, and
critical p values were Bonferroni corrected (*p % 0.05, **p %
0.01, ***p% 0.001).Results
Individuals with FMD with and without FLNA
Mutations are Phenotypically Similar
We ascertained a cohort of 19 individuals with FMD
without FLNA mutations. Clinically, they are very
similar to FMD individuals with FLNA mutations, apart
from an increased incidence of keloid formation17,18
(Figure 1, Table 1). Core features of the phenotype
include prominent supraorbital ridges, hyperostosis,
downslanting palpebral fissures, hypertelorism, and a
wide nasal bridge. The chin is typically small and pointed
(Figure 1A). Progressive contractures of the joints are, 2016
Figure 1. Clinical Images of Individuals with FMD
(A) Characteristic facial features, including supraorbital hyperostosis, downslanting palpebral fissures, hypertelorism, a broad nasal
bridge, and a small pointed chin. Panels, from left to right, show subjects 14, 05, (both TAK1 p.Pro485Leu), and 17 (TAB2 p.Glu569Lys).
(B) Limb abnormalities include contractures of the metacarpophalangeal and interphalangeal joints (subjects 01 and 17) and valgus
deformity of the foot (subject 14).
(C and D) Radiological assessment reveals (C) a dense, sclerotic skull, especially around the frontal bone and skull base (subjects 09 and
08) and (D) undermodeled phalanges, metatarsals, andmetacarpals (subjects 01, 05, and 13) with occasional metacarpal synostosis (sub-
ject 01), scoliosis and undermodeled ribs (subject 08), and splaying of the metaphysis of the tibia and femur with bowing (subjects 01
and 02).
(E) Keloid scar formation in subjects 11 and 05.common, especially in the fingers and wrists (Figure 1B).
Radiographs show a dense skull, especially the frontal
bone and skull base (Figure 1C). The long bones of
the hands and feet are undermodeled, frequently with
sclerotic cortices (Figure 1D). Subjects often present
with mild to severe scoliosis and have undermodeled,
deformed ribs, sometimes with a ‘‘coat-hanger’’ con-
figuration. The long bones have dense cortices and
splaying of the metaphyses (Figure 1D). Three subjects
had a somewhat milder skeletal phenotype (07, 18, and
19; Table 1), and individual 07 lacked a number of facial
characteristics but still had prominent supraorbital
ridges. Of the 19 individuals listed in Table 1, eight
(two male, six female) exhibit keloid scarring that is
occasionally progressive and severe and has the potential
to form either spontaneously or after surgical trauma
(Figure 1E).The AmerMutations in MAP3K7 and TAB2 Cause FMD
Whole-exome sequencing in family trios identified three
individuals (01, 02, and 05) with the same de novo
missense mutation, c.1454C>T, in MAP3K7 ([GenBank:
NM_003188.3] Table 2). The subjects each had no more
than three non-synonymous, validated de novomutations
in total across their respective exomes (Tables S3–S4). The
recurrent mutation is predicted to substitute a proline to
a leucine at position 485 (p.Pro485Leu) of the protein
product ofMAP3K7, TAK1. Subsequently, an additional in-
dividual (subject 12) was independently found, via exome
analysis, to have the same de novo mutation.
Sequencing of another family trio (subject 17,
Figure 1A, right panel) demonstrated a de novo missense
variant, c.1705G>A, in TAB2 (MIM: 605101 [GenBank:
NM_015093.5]), which encodes the binding partner of
TAK1, TAK1-associated binding protein 2 (TAB2).22 Thisican Journal of Human Genetics 99, 392–406, August 4, 2016 395
variant substitutes a glutamic acid to a lysine at position
569 (p.Glu569Lys) of TAB2 and was confirmed by Sanger
sequencing. This individual had one other de novo
variant in EFHC1: c.674C>G (p.Thr225Ser [GenBank:
NM_018100.3]). Missense mutations in this region of
EFHC1 are associated with juvenile absence or myoclonic
epilepsy.23,24 Because individual 17 has no history of sei-
zures and because TAB2 is known to directly interact
with and stabilize TAK1,22 the TAB2 mutation was priori-
tized for further analysis.
Further exome analysis and targeted Sanger sequencing
of the exons of MAP3K7 and TAB2 in the remaining indi-
viduals with unsolved cases of FMD found that another
11 individuals have the recurrent c.1454C>TMAP3K7mu-
tation and an additional subject (07) was found to have
novel de novo mutation in MAP3K7: c.502G>C, predict-
ing the substitution p.Gly168Arg in TAK1 (Table 2). In
addition, two unrelated individuals (18 and 19) who
share the FMD phenotype with their respective mothers
were found to have missense mutations in MAP3K7:
c.208G>A and c.299T>A, predicting the substitutions
p.Glu70Gln and p.Val100Glu, respectively. Both of these
mutations were shown to have been inherited from the
proband’s affected mother. In both instances, maternal
grandparental samples were not available to ascertain if
they had arisen de novo or not.
The phenotype of individuals with the recurrent
c.1454C>T mutation is not noticeably different from
that of subject 17, who has the missense mutation in
TAB2 (Table 1; Figure 1A, right panel). The presentation
of subject 07 with the p.Gly168Arg TAK1 substitution is,
however, milder than that of the rest of the cohort. Indi-
viduals 18 and 19 (p.Glu70Gln and p.Val100Glu, respec-
tively) have a typical facial appearance for FMD; however,
the skeletal presentation is milder (Table 1). Only individ-
uals with the TAK1 p.Pro485Leu substitution developed
keloid scarring (Table 1).
Altogether, we found four variants in MAP3K7 to be
causative of FMD in a total of 18 individuals. In the single
remaining individual in this cohort, a missense mutation
was identified in TAB2, which encodes for a protein that
interacts directly with TAK1, the protein specified by
MAP3K7.
TAK1 and TAB2 Mutations Predict Substitutions in
Functionally Relevant Conserved Domains
Our genetic studies identified five different missense muta-
tions affecting two proteins that form part of the TAK1
complex. MAP3K7 encodes TAK1, a MAP-3 kinase and
the core enzymatic component of a multiprotein complex
that is a hub for the control of many signaling pathways.25
TAB2 encodes TAB2, a scaffolding protein necessary for the
activation of some of signaling properties of TAK1,22
although it has not been shown to possess enzymatic activ-
ity itself.
TAK1 is comprised of an N-terminal kinase domain, a
poorly characterized linker region, and a C-terminal396 The American Journal of Human Genetics 99, 392–406, August 4coiled-coil domain25,26 (Figure 2). Pro485 in TAK1, which
is substituted to a leucine in 15 unrelated individuals
with FMD, is phylogenetically highly conserved and the
residue is invariant in both vertebrates and invertebrates,
including C. elegans (genomic evolutionary rate profiling
[GERP] score of 5.79, Figure 2A). The substitution occurs
within the C terminus of TAK1 immediately N-terminal to
the coiled-coil domain within a region that mediates
interactions with TAB227 and that might also constitute a
homodimerization interface28 (Figure 2B). A crystal struc-
ture is available for the N-terminal kinase domain29 but
not for the linker region or C terminus, and therefore the
structural consequences of substituting Pro485 cannot
be ascertained. Variant effect prediction software (Poly-
Phen-2, MutationTaster, and SIFT) estimates that the recur-
rent p.Pro485Leu substitution is likely to be deleterious
(PolyPhen score of 0.992, probably damaging; Muta-
tionTaster score of 0.999, disease causing; SIFT score of 0,
damaging).
Similarly, thep.Glu70Gln, p.Val100Glu, andp.Gly168Arg
substitutions lie within a stretch of 120 almost completely
conserved residues in seven vertebrates. A glutamine at posi-
tion 70 is conserved to Drosophila (GERP score, 5.22), and a
valine at position 100 is conserved in the seven vertebrate
homologs analyzed (GERP score, 5.67; Figure 2A). Both are
predicted to be disease causing and have PolyPhen scores
of 0.995 and 0.951, respectively (probably damaging),
MutationTaster scores of 0.999 (disease causing), and SIFT
scores of 0 (damaging). A glycine at position 168 is con-
served inDrosophila (GERP score, 5.18; Figure 2A). PolyPhen
(0.802, possibly damaging), MutationTaster (0.999, disease
causing), and SIFT (0, damaging) predict this substitution
to be disease causing. These three substitutions lie within
the conserved kinase domain of TAK1 (Figure 2B). Predic-
tions based on the published crystal structure29 (TAK1-
TAB1 fusion protein [PDB: 2EVA]) of this region of the
protein suggest that the p.Gly168Arg substitution would
disrupt a tightly constrained b-hairpin turn that is required
to order the active site of the kinase domain (Figure 2C).
Glu70 is close to an important loop that sits over the active
site of the TAK1 enzyme; however, substitution to a
glutamine is conservative and it might establish similar
interactions within the structure. Val100 is located in a hy-
drophobic pocket with Ile65, Phe74, Arg71, and Leu97,
and substitution to a glutamic acid could be destabilizing
to this region (Figure 2C).
Prediction of the effect of the TAB2 variant
(p.Glu569Lys) is constrained by limited data on this pro-
tein. The substitution has a PolyPhen-2 score of 0.989
(probably damaging), a MutationTaster score of 0.999 (dis-
ease causing), and a SIFT score of 0 (damaging), suggesting
the potential for pathogenicity. Glu569 lies in an area
of high conservation in vertebrates (GERP score, 5.06;
Figure 2A), but no tertiary structure for this protein is
available. Similar to TAK1, TAB2 has a C-terminal coiled-
coil domain within which the TAK1 binding domain
resides.22,27 The p.Glu569Lys substitution is located five, 2016
Table 1. Clinical and Radiographic Characteristics of Individuals with FMD
Subject Sex
Clinical Features
Supraorbital
Ridges
Small
Chin
Hearing
Loss Hypertelorism
Downslanting
Palpebral
Fissures
Wide Nasal
Bridge
Cleft
Palate/Bifid
Uvulaa
Congenital
Stridor/Subglottic
Stenosis
01 M þ þ þ þ þ þ – þ
02 M þ þ þ þ þ þ þ þ
03 M þ – þ þ þ þ – U
04 M þ – þ þ þ þ U U
05 M þ þ þ þ þ þ – –
06 M þ þ U þ þ þ – –
07 M þ – – þ – þ – –
08b M þ þ þ þ – þ – þ
09 F þ þ þ þ þ þ þ –
10b F þ þ þ þ þ þ – –
11b F þ – þ þ þ þ – þ
12 F þ þ þ þ þ þ þ þ
13b F þ þ þ þ þ þ þ þ
14 F þ þ U þ þ þ – U
15 F þ þ þ þ þ þ þ –
16b F þ þ þ þ þ þ – –
17 F þ þ þ þ þ þ – –
18b F þ þ þ þ þ þ – U
19 F þ þ – þ þ þ – –
þ, present; , absent; (þ), equivocal; U, unknown; M, male; F, female.
aIncluding submucous cleft palate.
bReported in Basart et al.17 or Morava et al.18.residues N-terminal to this mapped TAK1 binding interface
(residues 574–693, Figure 2B).
To evaluate the consequences of the recurrent MAP3K7
c.1454C>T mutation at the level of the transcript,
cDNA was prepared from cultured primary fibroblasts ob-
tained from subjects 02, 13, and 16 (MAP3K7 c.1454C>T)
and RT-PCR followed by Sanger sequencing was per-
formed. Sequence chromatograms demonstrated the
persistence of the mutant allele in all instances and no
additional RT-PCR products were observed (data not
shown). An RNA source for subjects 07, 17, 18, and 19
was not available to test these alternative mutations in
a similar manner. Together, these genetic, bioinformatic,
and phylogenetic data constitute conclusive evidence
that mutations in MAP3K7 cause frontometaphyseal
dysplasia.
To explore the mechanism by which mutations confer
this phenotype, we first considered a hypothesis that in-
vokes haploinsufficiency for the pathogenesis of this
form of FMD. Individuals with haploinsufficiency en-
compassing the MAP3K7 locus30 and mice with condi-
tional knockout of Map3k7 in the skeleton do not haveThe Ameran osteosclerotic phenotype,31,32 suggesting that the
phenotype arising from theMAP3K7mutations described
here is not a result of haploinsufficiency. To further test
the hypothesis that the mutations in MAP3K7 do not
exhibit their pathogenic effect by affecting the stability
of TAK1, we performed quantitative western blots on
lysates prepared from cycloheximide-treated cells trans-
fected with expression constructs specifying either
WT TAK1 (TAK1WT) or TAK1 with the p.Pro485Leu
(TAK1p.Pro485Leu) or the p.Gly168Arg (TAK1p.Gly168Arg)
substitutions. There was no difference in protein stability
between mutant TAK1 and WT protein up to 8 hr after
cycloheximide treatment (Figure 2D), indicating that
the pathogenic effect of these alleles is unlikely to relate
to destabilization of the protein product. Similarly, indi-
viduals with haploinsufficiency of TAB2 have no skeletal
dysplasia and instead present with cardiac malforma-
tions,33 and Tab2-knockout mice die in utero of liver
degeneration.34 These data therefore suggest that the
phenotype of the individual described here with a
missense mutation at this locus is unlikely to arise from
a haploinsufficient mechanism.ican Journal of Human Genetics 99, 392–406, August 4, 2016 397
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– þ – – þ þ þ U (þ)The p.Pro485Leu Substitution Does Not Affect TAK1/
TAB2 Binding or TAK1 Homodimerization
A parsimonious hypothesis for the mechanism leading to
FMD in these individuals would be that causative muta-
tions disrupt the interaction between TAK1 and TAB2 given
that both the recurrent mutation and the substitution in
TAB2 lie within (or very close to) the interface formed by
both proteins.27 We used competitive co-immunoprecipita-
tion to examine the relative TAB2 binding affinity of
p.Pro485Leu in the presence of TAK1WT by using a transient
transfection protocol in HEK293FT cells. Two differentially
tagged TAK1 proteins, with one construct specifying the
p.Pro485Leu substitution and the other WT, were trans-
fected alongside TAB2, and immunoprecipitation was per-
formed to measure the relative ability of these proteins to
bind TAB2. No significant difference is observed between
TAK1WT and TAK1p.Pro485Leu in their ability to bind TAB2
(p ¼ 0.59; unpaired t test, Figure 3A), indicating that this
interaction is physically unimpaired by the presence of
the p.Pro485Leu substitution in TAK1.
A second hypothesis relates to the possibility that TAK1
homodimerizes28 and that this activity impacts regulation398 The American Journal of Human Genetics 99, 392–406, August 4of the signaling functions of the TAK1 complex. The TAK1
homodimerization interface has been mapped within the
coiled-coil domain to a region that is adjacent to, but not
overlapping, Pro485.28 We tested the capacity of TAK1WT
to dimerize with TAK1p.Pro485Leu by using competitive co-
immunoprecipitation. Again, no significant difference
(p ¼ 0.37; unpaired t test) is noted between the formation
of TAK1WT/WT homodimers and TAK1p.Pro485Leu/WT hetero-
dimers, suggesting that the p.Pro485Leu substitution does
not impair this activity (Figure S2).
TAK1p.Pro485Leu and TAK1p.Gly168Arg Increase TAK1
Autophosphorylation
In the absence of a clear mechanism relating the p.Pro485-
Leu substitution to mapped protein-protein interactions
within the C terminus of TAK1, we sought evidence that
this substitution altered the kinase activity of this pro-
tein. Upon activation, TAK1 is sequentially autophos-
phorylated within its kinase domain,35 starting at Ser192
and followed by Thr178, Thr187, and Thr184, which in
turn triggers the phosphorylation of a number of down-
stream effectors.35–37 In addition to being scaffolded by, 2016
Table 2. Mutations in MAP3K7 and TAB2, Paternal Age at Birth, and Ancestry of Individuals with FMD
Subject Gene DNA Protein Inheritance
Paternal Age at Birth
of Proband (Years)a Ancestry
01 MAP3K7 c.1454C>T p.Pro485Leu de novo 33 Italian
02 MAP3K7 c.1454C>T p.Pro485Leu de novo 40 English
03 MAP3K7 c.1454C>T p.Pro485Leu U 36 Austrian
04 MAP3K7 c.1454C>T p.Pro485Leu U 38 Australian-European
05 MAP3K7 c.1454C>T p.Pro485Leu de novo 26 Scottish
06 MAP3K7 c.1454C>T p.Pro485Leu U 32 Swiss
08 MAP3K7 c.1454C>T p.Pro485Leu U 28 Korean
09 MAP3K7 c.1454C>T p.Pro485Leu U 18 Hispanic
10 MAP3K7 c.1454C>T p.Pro485Leu U 46 Turkish
11 MAP3K7 c.1454C>T p.Pro485Leu U 47 Mexican
12 MAP3K7 c.1454C>T p.Pro485Leu de novo 35 German
13 MAP3K7 c.1454C>T p.Pro485Leu U 26 English
14 MAP3K7 c.1454C>T p.Pro485Leu de novo 41 German
15 MAP3K7 c.1454C>T p.Pro485Leu U 30 Dutch
16 MAP3K7 c.1454C>T p.Pro485Leu de novo 40 Australian-European
18 MAP3K7 c.208G>C p.Glu70Gln dominant U French-Canadian
19 MAP3K7 c.299T>A p.Val100Glu dominant U Hungarian
07 MAP3K7 c.502G>C p.Gly168Arg de novo 28 Brazilian
17 TAB2 c.1705G>A p.Glu569Lys de novo U Australian-European
U, unknown.
aMean, 34.4 and SD, 7.9.TAB2, signaling through the TAK1 complex is also depen-
dent on a second interacting factor, TAB1 (TAK1-associated
binding protein 1 [MIM: 602615]).26 To test whether
the mutations leading to FMD affect TAK1 autophos-
phorylation, MAP3K7 constructs specifying TAK1WT,
TAK1p.Pro485Leu, and TAK1p.Gly168Arg were expressed in
HEK293FT cells alongside constructs encoding its acti-
vating proteins TAB1 and TAB2. Under these conditions,
quantitative western analysis revealed that both
TAK1p.Pro485Leu and TAK1p.Gly168Arg are significantly more
phosphorylated at Thr187 than TAK1WT (p ¼ 0.00014
and p ¼ 0.00010 respectively; unpaired t tests; Figure 3B).
Consistent with the established facultative requirement
for the co-activator TAB1 in mediating TAK1 autophos-
phorylation, no difference in the phosphorylation of
TAK1 mutants was observed when TAK1 was expressed
with TAB2 alone (Figure S3A).
The p.Pro485Leu Substitution Alters Signaling
Downstream of the TAK1 Complex
Enhanced autophosphorylation of TAK1 in the presence of
substitutions that lead to FMD suggests that signaling
pathways downstream of this complex should exhibit
altered activity. Multiple signaling pathways are activated
downstream of TAK1, including JNK,38 p38 MAPK,39 andThe AmerNF-kB40 (Figure 4A). We first employed a luciferase reporter
assay (Pathdetect, Agilent) that measures a global readout
for transcriptional activation mediated by several MAPK
targets, including ERK, p38, and JNK. A significantly
enhanced activation of the reporter is observed for
TAK1p.Pro485Leu in comparison to TAK1WT (Figure 4B).
Given that this reporter system detects activity mediated
via a number of MAPK pathway effectors, and considering
the documented specific role for p-p38 downstream of
TAK1 in the maintenance of bone mineralization in the
mouse,31 p-p38 was also assayed by western blot
(Figure 4C). These data indicate that the TAK1p.Pro485Leu
construct results in a substantial increase in phosphoryla-
tion of p38 compared to that mediated by TAK1WT.
Notably however, neither MAPK signaling nor p-p38 are
increased when TAK1p.Gly168Arg is expressed under the
same experimental conditions (Figures 4B and 4C), despite
the significant increase in autophosphorylation noted in
TAK1p.Gly168Arg.
The second signaling pathway relevant to skeletogene-
sis that we evaluated was that mediated by NF-kB.32,41
NF-kB is essential for RANK-L-mediated osteoclast differ-
entiation,42,43 whereas its activation inhibits osteoblasto-
genesis.41 We used a luciferase reporter sensitive to
activation of this pathway and found that both theican Journal of Human Genetics 99, 392–406, August 4, 2016 399
Figure 2. Conservation and Structural Consequences of Substitutions in TAK1 and TAB2
(A) The residues mutated in FMD2 are conserved to C. elegans at TAK1Pro485, to D. melanogaster at TAK1Glu70 and TAK1Gly168, and to
zebrafish at TAK1Val100 and TAB2Glu569. Sequences were obtained from the Ensembl Genome browser and aligned with Clustal Omega
(European Bioinformatics Institute).
(B) All five substitutions are found within regions of functional significance; p.Glu70Gln, p.Val100Glu, and p.Gly168Arg are located in
the middle of the kinase domain (magenta), p.Pro485Leu is located within the TAB2 binding domain on TAK1 (light blue), and
p.Gly569Lys is within the coiled-coil domain, of TAB2, which is within the region mapped as critical for TAK1 binding.27
(C) Crystal structure for the N-terminal 303 amino acids of TAK1; Gly168 is located within a tight b-hairpin turn. Substitution to an argi-
nine at this site has the potential to disrupt the kinase domain. Glu70 is close to a peptide loop that sits over the active site of the TAK1
enzyme, and substitution to a glutamine is conservative. Val100 is located in a hydrophobic pocket along with Ile65, Phe74, Arg71, and
Leu97, and substitution to a glutamic acid could be destabilizing to this region.
(D) TAK1p.Pro485Leu and TAK1p.Gly168Arg do not alter the stability of TAK1 when normalized to TAK1WT up to 8 hr after cycloheximide
treatment of transfected cells.
Error bars show SD.TAK1p.Pro485Leu and the TAK1p.Gly168Arg (Figure 4D) substi-
tutions confer significantly reduced reporter activity in a
transient transfection assay (Figure 4D). Together, these
results indicate that signaling emanating from the TAK1
complex is altered by TAK1p.Pro485Leu, but that the degree
and quality of this disturbance is not exactly mirrored by
the TAK1p.Gly168Arg substitution even though both vari-
ants enhance the autophosphorylation of the enzyme
and the phenotypic consequences in the subjects with
these variants are similar.
The p.Glu569Lys Substitution in TAB2 Alters MAPK
Signaling
The observation of a single instance of a de novo
missense variant in TAB2 in an individual with FMD
does not, in itself, constitute sufficiently strong evidence
for pathogenicity. However, the location of this variant400 The American Journal of Human Genetics 99, 392–406, August 4close to the mapped binding interface for TAB2 and
TAK1 in an individual who demonstrates a pheno-
type that is indistinguishable from individuals with
MAP3K7-associated FMD presents a strong a priori case
for further investigation. We first questioned whether
equivalent alterations to those observed in expression as-
says using the TAK1p.Pro485Leu construct in signaling were
conferred by the de novo mutation in TAB2. We found
that the presence of the TAB2p.Glu569Lys substitution al-
ters neither TAK1 autophosphorylation (Figure 3B) nor
NF-kB signaling activity (Figure 4D). There is, however,
a clear increase in MAPK luciferase reporter activity and
an increased p-p38/p38 ratio (Figures 4B and 4C), indi-
cating that, despite a lack of enhanced autophosphoryla-
tion of TAK1, this variant in TAB2 has a strong effect on
the activity of downstream components of the MAPK
pathway., 2016
Figure 3. The Recurrent TAK1Pro485Leu Substitution Does Not Impair TAB2 Binding but Increases Autophosphorylation of TAK1
(A) Competitive co-immunoprecipitation between FLAG-TAK1WTor FLAG-TAK1p.Pro485Leu and HA-TAB2 shows no significant difference
between TAK1WT and TAK1p.Pro485Leu in terms of their ability to bind TAB2 in the presence of TAK1WT.
(B) When expressed in HEK293FT cells, TAK1p.Pro485Leu and TAK1p.Gly168Arg have significantly increased phosphorylation when
expressed with TAB1 and TAB2WT in comparison to TAK1WT. In contrast, when TAK1WT is expressed with TAB1 and TAB2p.Glu569Lys, there
is no increased phosphorylation of TAK1. Detection of FLAG was used for the quantification of TAK1.
Error bars show SD.Other Substituting Residues at TAK1 Pro485 Alter
TAK1 Activity
Clinically, only the proline to leucine substitution is
observed at position 485 in TAK1 in this cohort of indi-
viduals with FMD. Other mutations at this codon, how-
ever, might occur and lead to similar biochemical and
clinical consequences. The likelihood of this might be
dependent on the mode of gain of function and whether
this primarily relates to the substitution of Pro485 and/or
the identity of the substituting residue. We therefore
examined the effect of other substitutions at the
Pro485 codon to test the possibility that they might
also confer a gain of function. Both p.Pro485Arg andThe Amerp.Pro485Ala substitutions did enhance autophosphoryla-
tion (Figure S3B) and also had a variable effect on lucif-
erase-based reporter assays for MAPK and NF-kB tran-
scriptional targets. Substitution to an amino acid with a
bulky and/or charged side chain (p.Pro485Arg) conferred
more alteration in these signaling pathways than more
conservative missense substitutions (e.g., p.Pro485Ala
and p.Pro485Ser). Although TAK1p.Pro485Arg shows no
increase in MAPK activity (Figure S4A), it does show a
significant increase in p-p38 when measured on immu-
noblot, in addition to significantly decreased NF-kB ac-
tivity (Figures S4B and S4C). Substitutions to residues
with smaller and less polar side chains (Ser and Ala) resultican Journal of Human Genetics 99, 392–406, August 4, 2016 401
Figure 4. Both MAPK and NF-kB Signaling Activity Are Altered by TAK1 and TAB2 Substitutions
(A) Activated TAK1 has the ability to activate numerous downstream pathways, including those leading to the activation of the kinases
JNK and p38, and the pro-inflammatory transcription factor NF-kB.
(B and C) Luciferase reporter for MAPK activity (B) and an immunoblot for phosphorylated-p38 (C), demonstrating that both
TAK1p.Pro485Leu-TAB2WTand TAK1WT-TAB2p.Glu569Lys combinations are associated with significantlymore activatedMAPK in comparison
to combinations of WT constructs in HEK293 cells. TAK1p.Gly168Arg-TAB2WT is not significantly different from TAK1WT-TAB2WT.
(D) The activity of an NF-kB luciferase reporter showed that TAK1p.Pro485Leu and TAK1p.Gly168Arg have significantly reduced NF-kB activity
in comparison to TAK1WT, whereas TAB2p.Glu569Lys was no different than TAK1WT expressed with TAB2WT.
Error bars show SD.in no difference in signaling, as assayed either through
reporter assays or p38 phosphorylation, except for a
small but significant increase in p-p38 with
TAK1p.Pro485Ser (Figure S4B). Overall, the changes in
signaling function are smaller in magnitude to those
conferred by the clinically observed substitution to
leucine. We conclude that the identity of the substituting
amino acid at this position does influence TAK1 function
and that these substitutions also hold the potential to be
disease causing.
Discussion
Until now, mutations in only one gene, FLNA, have been
shown to cause FMD.4 Here, we have used a combination
of exome and targeted Sanger sequencing to reveal four
mutations in MAP3K7 to be the cause of FMD in 18 unre-
lated individuals and another variant in the gene encoding
the interacting protein TAB2 to be likely causative of the
condition in an additional individual. A specific mutation
introducing a p.Pro485Leu substitution at the boundary of
the C-terminal coiled-coil domain of the MAP-3 kinase,402 The American Journal of Human Genetics 99, 392–406, August 4TAK1, was present in 15 unrelated individuals from diverse
ethnic backgrounds. In all instances where parental sam-
ples were available (n ¼ 6), this mutation had arisen de
novo. A second de novo mutation predicting the substitu-
tion p.Gly168Arg was found in the highly conserved
kinase domain of TAK1 in one individual. Two additio-
nal missense mutations leading to the substitutions
p.Glu70Gln and p.Val100Glu, both inherited from a simi-
larly affected parent, were found in another two subjects.
We propose that the X-linked form of FMD be henceforth
referred to as FMD1 to underscore its inheritance pattern
and that the autosomal-dominant phenotype described
here and caused by mutations inMAP3K7, the gene encod-
ing TAK1, be denoted as FMD2. Although the de novo
variant observed in TAB2 is an observation confined to a
single individual, the functional relationship that this pro-
tein has with TAK1 and the biochemical activity it confers
on the TAK1 signaling complex presents a strong, but still
provisional, case that it also be considered causative of
FMD. For this reason, we suggest that TAB2 will eventually
be shown to represent a third causative locus and that this
form of FMD will be denoted as FMD3., 2016
Phenotypically, there might be some differences be-
tween FMD1, FMD2, and TAB2-related FMD. Subjects
with substitutions in the kinase domain of TAK1 have
a notably milder phenotype than those with TAK1
p.Pro485Leu substitutions or TAB2- or FLNA- associated
FMD, suggesting a phenotype-genotype correlation. We
noted that the individuals with the recurrent substitution
in TAK1 have a higher incidence of cleft palate (n ¼ 5/16,
or 31% of subjects, compared to 9% reported in
FMD1).3,17,44 We also previously reported a higher inci-
dence of keloid scarring in individuals with FMD2 caused
by TAK1p.Pro485Leu.17 This is notable because keloid is a
rare phenotypic manifestation in Mendelian disorders,
and the data presented here could increase the understand-
ing of the pathogenesis of spontaneous keloid formation.
Keloid might only very occasionally appear as a feature
of FMD1,3 but a recently described novel filaminopathy
caused by a specific missense mutation in FLNA
(c.4726G>A [p.Gly1576Arg] [GenBank: NM_001110556.
1]) is also characterized by keloid scarring, joint contrac-
tures, and heart and kidney abnormalities. As such, it is
reminiscent of FMD without its skeletal manifesta-
tions.45,46 Therefore, it is possible that TAK1 and filamin
A operate in the same pathway to promote keloid forma-
tion, a possibility consistent with data that indicate that
activation of the TGF-b pathway, upstream of the MAP ki-
nases p38, ERK, and JNK, has an important role in keloid
pathogenesis. Small-molecule inhibition of p38, ERK,
and JNK in cultured keloid fibroblasts impairs collagen
accumulation and keloid development after TGFb stimula-
tion,47 and therefore attention to therapeutic targets for
keloid could usefully be focused on the pathway that links
filamin A, TAK1, TGF-b, and MAP kinases.
FMD2 is primarily caused by TAK1p.Pro485Leu in the
cohort presented here (15/18 individuals). The finding of
a highly recurrent mutation is consistent with a gain-of-
function mechanism. Although instances of highly recur-
rent mutations can be the result of a paternal-age
effect,48,49 we only demonstrated a modest signal for this
once we tabulated the age of the fathers at the birth of
the TAK1p.Pro485Leu individuals (Table 2).48 A more salient
observation is that the MAP3K7 mutation occurs at a hy-
permutable CpG dinucleotide and therefore the observa-
tion of a C>T transition is expected to be more common
than other mutations at this site.50,51We predict that other
substitutions at the Pro485 codon will exist and be associ-
ated with FMD phenotypes, but these have not been iden-
tified in this study, perhaps because of an ascertainment
bias or because of the small number of individuals studied
here. It might be relevant to note that a less significant ef-
fect on downstream signaling is observed when Pro485 is
replaced with residues other than leucine, and so if indi-
viduals do exist with alternative residues replacing
Pro485, they might present with a milder phenotype.
The structural and biochemical reasons for why
TAK1p.Pro485Leu is specifically implicated in this gain of
function remain enigmatic. The TAK1p.Pro485Leu substitu-The Amertion does not impair TAB2 binding, homodimerization,
or TAK1 stability. We note that Pro485 lies within a
consensus sequence for prolyl hydroxylation (LXXLAP)
as represented in other proteins,52–54 but efforts to demon-
strate that this site is subject to this form of modification
by using mass spectroscopy, peptide substrates, and co-
expression with prolyl hydroxylases failed to reveal any
evidence to support this hypothesis (data not shown).
Furthermore, substitution at this site with residues other
than leucine did not invariably confer the same effect on
autophosphorylation or signaling.
TAK1 is a MAP-3 kinase.37 On activation, it binds its co-
activators TAB1 and TAB2, leading to autophosphoryla-
tion, triggering downstream phosphorylation cascades.37
The de novo TAK1 substitutions p.Pro485Leu and
p.Gly168Arg significantly increase TAK1 autophosphory-
lation. The activated TAK1 complex is able to coordinate
signaling in a number of different pathways, including
the regulation of both osteoblast differentiation and activ-
ity.31,55 The p38 pathway is especially critical because p38
phosphorylates and activates RUNX2, the master differen-
tiation factor for osteoblasts, and DLX5, a transcription
factor that stimulates the expression of the osteoblast
genes IBSP (integrin-binding sialoprotein) and SP7 (os-
terix).31,55 TAK1p.Pro485Leu leads to increased phosphoryla-
tion of p38 and an enhanced ability to activate a generic
MAPK transcriptional reporter. The TAK1p.Gly168Arg substi-
tutions did not show the same ability to activate down-
stream MAPK cascades; this could reflect the noticeably
milder phenotype in this individual and the lack of sensi-
tivity of our assays to detect subtle changes in signaling
outputs. The TAB2 substitution p.Glu569Lys also increases
MAPK signaling and enhances phosphorylation of p38,
although these effects are not associated with activation
of TAK1 via detectably enhanced autophosphorylation.
Not only is p38 essential for osteoblast differentiation,31
it is also critical for the proper differentiation of osteoclasts
in response to RANK-L.56 Therefore a gain of function in
p38 signaling in both cell types is predicted to result in
both increased osteoblast differentiation and activity and
increased osteoclast differentiation. Further evidence that
p38 is a central, but not necessarily exclusive, mediator
of TAK1-directed osteogenesis, is the observation that
the osteopenia observed in mice with Map3k7 deleted in
the osteoblastic lineage is attributable to reduced p38
activation.31
The signaling output of TAK1 is complex and multifar-
ious and also includes regulation of NF-kB.57 Whereas
MAPK signaling promotes the development of both the
osteoblastic and osteoclastic lineage, NF-kB has opposing
effects. Its activation by inflammatory cytokines is gener-
ally inhibitory for osteoblastogenesis41,58 but essential for
osteoclastogenesis stimulated by RANK and RANK-L.42,43
Mice with an osteoclast-specific knockout of TAK1
have an osteopetrotic phenotype because of decreased
NF-kB activation, demonstrating that TAK1 is necessary
for proper osteoclast differentiation.32 Reduced NF-kBican Journal of Human Genetics 99, 392–406, August 4, 2016 403
signaling could therefore promote hyperostosis by acting
in concert in both of these cell types. Our data indicate
that the TAK1p.Pro485Leu and TAK1p.Gly168Arg variants are
associated with diminished NF-kB signaling, which is
also the effect observed in an osteoclast-specific knockout
of Map3k7 in mice. Hence, we conclude that activity
conferred by TAK1 substitutions cannot be attributed to a
simple biochemical gain-of-function mechanism across
all affected pathways given that it is clear that the
TAK1-complex variants alter multiple outputs, in different
directions. This could be especially important for
TAK1p.Gly168Arg, which does not increase MAPK signaling
output but does decrease NF-kB activity. This could still,
therefore, disrupt the overall ratio of MAPK to NF-kB
signaling and cause a milder FMD phenotype. Addition-
ally, our in vitro data indicate that the TAB2p.Glu569Lys sub-
stitution confers no difference in NF-kB signaling but still
results in a florid FMD phenotype. Overall, this suggests
that the combinatorial effect of these variants on all
signaling pathways involved will likely only be definitively
established once they can be evaluated in bone tissue from
animal models of this disorder.
The TAB2p.Glu569Lys substitution does not increase TAK1
autophosphorylation, nor does it decrease NF-kB signaling
output. TAB2 has a number of TAK1-independent func-
tions, and therefore the phenotype arising from this substi-
tution could be attributed to these activities. For instance,
TAB2 has been shown to localize in the nucleus with tran-
scriptional repressors N-CoR and HDAC3, where it acts to
repress gene targets of NF-kB; the complex is exported
out of the nucleus upon stimulation of the TAK1 com-
plex.59 Additionally, TAB2 has been shown to bind
Smad7 downstream of TGF-b activation, which blocks
TAK1-TAB2-TRAF2 complex assembly.60 Taken together,
these data suggest that TAB2 acts to repress signaling medi-
ated by TAK1, but it is unknown whether TAB2 might also
act to promote MAPK functions, although our results indi-
cate that the Glu569Lys substitution does confer such
activity.
As well as influencing major developmental mechanisms
in the skeleton, TAK1 has a headline role governing the
innate immune response and inflammation.40 The TAK1
complex is activated by inflammatory cytokines (e.g., TNF-
a40 and IL-161) and triggers downstream signaling responses
to these stimuli, such as activation of NF-kB.40,62 We expect
that individualswithgain-of-functionTAK1 signalingmight
presentwith inflammatory phenotypes; however, this is not
a clinicallyapparent aspectof theFMD2phenotype. Focused
study from this point could reveal hitherto unexpected sub-
clinical anomalies in this disorder.
The TAK1 signaling complex is a broadly dispersed
signaling hub in multiple tissues. Our observation that
alteration of its signaling functions via a specific muta-
tional mechanism hints at levels of regulation of this com-
plex that remain uncharacterized. Although the pheno-
type of FMD extends to tissues other than bone, the
pronounced effect that these mutations have on the404 The American Journal of Human Genetics 99, 392–406, August 4mineralization of the skeleton suggests that understanding
the function of this signaling hub in this tissue could pro-
duce new insights and therapeutic options for conditions
characterized by osteopenia.Supplemental Data
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